WO2003057240A3 - Treatment and diagnosis of af4-dependant diseases - Google Patents

Treatment and diagnosis of af4-dependant diseases Download PDF

Info

Publication number
WO2003057240A3
WO2003057240A3 PCT/GB2003/000041 GB0300041W WO03057240A3 WO 2003057240 A3 WO2003057240 A3 WO 2003057240A3 GB 0300041 W GB0300041 W GB 0300041W WO 03057240 A3 WO03057240 A3 WO 03057240A3
Authority
WO
WIPO (PCT)
Prior art keywords
diagnosis
treatment
diseases
dependant
dependant diseases
Prior art date
Application number
PCT/GB2003/000041
Other languages
French (fr)
Other versions
WO2003057240A2 (en
Inventor
Ann Jacqueline Hunter
Peter Laurence Oliver
Adrian Michael Isaacs
Kay Elisabeth Davies
Original Assignee
Smithkline Beecham Plc
Medical Res Council
Chancellor
Ann Jacqueline Hunter
Peter Laurence Oliver
Adrian Michael Isaacs
Kay Elisabeth Davies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0200531A external-priority patent/GB0200531D0/en
Priority claimed from GB0200737A external-priority patent/GB0200737D0/en
Application filed by Smithkline Beecham Plc, Medical Res Council, Chancellor, Ann Jacqueline Hunter, Peter Laurence Oliver, Adrian Michael Isaacs, Kay Elisabeth Davies filed Critical Smithkline Beecham Plc
Priority to AU2003201641A priority Critical patent/AU2003201641A1/en
Publication of WO2003057240A2 publication Critical patent/WO2003057240A2/en
Publication of WO2003057240A3 publication Critical patent/WO2003057240A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Abstract

The use of AF4 polypeptides and polynucleotides in the design of protocols for the treatment of neurodegenerative diseases. The use of the polypeptides for diagnosis of neurodegenerative diseases is also disclosed.
PCT/GB2003/000041 2002-01-09 2003-01-07 Treatment and diagnosis of af4-dependant diseases WO2003057240A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003201641A AU2003201641A1 (en) 2002-01-09 2003-01-07 Treatment and diagnosis of af4-dependant diseases

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0200531.2 2002-01-09
GB0200531A GB0200531D0 (en) 2002-01-09 2002-01-09 New use
GB0200737.5 2002-01-11
GB0200737A GB0200737D0 (en) 2002-01-11 2002-01-11 New use

Publications (2)

Publication Number Publication Date
WO2003057240A2 WO2003057240A2 (en) 2003-07-17
WO2003057240A3 true WO2003057240A3 (en) 2003-09-25

Family

ID=26246932

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2003/000041 WO2003057240A2 (en) 2002-01-09 2003-01-07 Treatment and diagnosis of af4-dependant diseases

Country Status (2)

Country Link
AU (1) AU2003201641A1 (en)
WO (1) WO2003057240A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994026930A1 (en) * 1993-05-14 1994-11-24 Thomas Jefferson University Methods for screening and treating leukemias resulting from all-1 region chromosome abnormalities

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994026930A1 (en) * 1993-05-14 1994-11-24 Thomas Jefferson University Methods for screening and treating leukemias resulting from all-1 region chromosome abnormalities

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BIONDI A ET AL: "Detection of ALL-1/AF4 fusion transcript by reverse transcription-polymerase chain reaction for diagnosis and monitoring of acute leukemias with the t(4;11) translocation.", BLOOD. UNITED STATES 15 NOV 1993, vol. 82, no. 10, 15 November 1993 (1993-11-15), pages 2943 - 2947, XP009009482, ISSN: 0006-4971 *
LI QUANZHI ET AL: "AF4 encodes a ubiquitous protein that in both native and MLL-AF4 fusion types localizes to subnuclear compartments.", BLOOD, vol. 92, no. 10, 15 November 1998 (1998-11-15), pages 3841 - 3847, XP009009484, ISSN: 0006-4971 *
NILSON I ET AL: "Exon/intron structure of the human AF-4 gene, a member of the AF-4/LAF-4/FMR-2 gene family coding for a nuclear protein with structural alterations in acute leukaemia.", BRITISH JOURNAL OF HAEMATOLOGY. ENGLAND JUL 1997, vol. 98, no. 1, July 1997 (1997-07-01), pages 157 - 169, XP009009481, ISSN: 0007-1048 *
REICHEL MARTIN ET AL: "Rapid isolation of chromosomal breakpoints from patients with t(4;11) acute lymphoblastic leukemia: Implications for basic and clinical research.", CANCER RESEARCH, vol. 59, no. 14, 15 July 1999 (1999-07-15), pages 3357 - 3362, XP002238945, ISSN: 0008-5472 *
UCKUN F M ET AL: "Clinical significance of MLL-AF4 fusion transcript expression in the absence of a cytogenetically detectable t(4;11)(q21;q23) chromosomal translocation.", BLOOD. UNITED STATES 1 AUG 1998, vol. 92, no. 3, 1 August 1998 (1998-08-01), pages 810 - 821, XP002238944, ISSN: 0006-4971 *
WITTWER FRANZ ET AL: "Lilliputian: An AF4/FMR2-related protein that controls cell identity and cell growth.", DEVELOPMENT (CAMBRIDGE), vol. 128, no. 5, March 2001 (2001-03-01), pages 791 - 800, XP001098959, ISSN: 0950-1991 *

Also Published As

Publication number Publication date
AU2003201641A8 (en) 2003-07-24
AU2003201641A1 (en) 2003-07-24
WO2003057240A2 (en) 2003-07-17

Similar Documents

Publication Publication Date Title
AU2003243551A1 (en) Use of an anti-endotoxin drug in the prevention and treatment of disease
AU2002255248A1 (en) Diagnosis, treatment and research of mental disorders
AU2003265831A1 (en) Hyperspectral imaging of the human retina
IL174047A0 (en) Differentially expressed tumour-specific polypeptides for use in the diagnosis and treatment of cancer
AU2003300791A1 (en) Combination therapy for the treatment of pain
EP1487446A4 (en) Bicyclic heterocycles for the treatment of diabetes and other diseases
AU2003294217A1 (en) Human polypeptides encoded by polynucleotides and methods of their use
AU2001250978A1 (en) Polynucleotides and polypeptides, their use in diagnosis and treatment of cardiac, renal or inflammary disease
IL148401A0 (en) Hsp70-derived peptides and uses thereof in the diagnosis and treatment of autoimmune diseases
AU2003263628A1 (en) Medical treatment system for stimulating spots on the body suitable for acupuncture
AU2003286285A1 (en) Use of fgf-18 in the diagnosis and treatment of memory disorders
AU2003209150A1 (en) Combination for the treatment of immunoinflammatory disorders and proliferative skin diseases
AU2003238242A1 (en) Use of an anti-endotoxin drug in the prevention and treatment of disease
AU2003904328A0 (en) Diagnosis and treatment of neurodegenerative disorders
AU2002319286A1 (en) Skin treatment
TWI320413B (en) 1,4-diazabicyclo [ 3.2.2 ] nonanecarboxamide derivatives, preparation thereof and therapeutic use thereof
AU2003210266A1 (en) Treatment, diagnosis and imaging of disease
AU2002352566A1 (en) Use of corrinoids in the treatment of skin diseases
AU2002364808A1 (en) Polynucleotide and protein involved in synaptogenesis, variants thereof, and their therapeutic and diagnostic uses
AU2003245415A1 (en) Vehicle for the medical treatment of persons in remote areas
AU2003245858A1 (en) Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases
AU2003232699A1 (en) System and device for massage, pressure-treatment and heat-treatment of skin and parts of the body
AU2003256447A1 (en) Treatment of autoimmune skin diseases
WO2003057240A3 (en) Treatment and diagnosis of af4-dependant diseases
AU2003244455A1 (en) Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP